HealthcareServices

Chronic Pancreatitis (CP) Market Forecast 2026: Where the Industry Is Headed

February 23, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the chronic pancreatitis (cp) market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Chronic Pancreatitis (CP) Market in 2026, and what figure is it projected to hit by 2030?

The chronic pancreatitis (cp) market size has shown strong growth in recent years. It is expected to grow from $5.23 billion in 2025 to $5.56 billion in 2026, at a compound annual growth rate (CAGR) of 6.4%. The expansion observed in the historical period can be linked to improvements in diagnostic imaging availability, a rise in awareness of pancreatic disorders, the broader application of pain management therapies, the increasing scope of gastroenterology services, and enhanced supportive care options.

The chronic pancreatitis market size is projected for significant expansion in the coming years, anticipated to reach $7.05 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.1%. This growth in the forecast period can be attributed to the increasing development of advanced enzyme formulations, a rising focus on early-stage intervention, the expansion of outpatient treatment models, the growing integration of nutrition-based therapies, and increased investment in pancreatic disease research. Major trends expected during this period involve the increasing use of enzyme replacement therapies, the rising adoption of minimally invasive endoscopic treatments, a growing focus on nutritional management, the expansion of personalized treatment plans, and an enhanced emphasis on early diagnosis.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21146&type=smp

Which Drivers Are Affecting Market Participation In The Chronic Pancreatitis (CP) Market?

The chronic pancreatitis market is projected to expand due to the rising intake of alcohol. Alcohol consumption involves drinking ethanol-containing beverages, typically for social, recreational, or cultural reasons, but excessive intake can result in health issues or dependence. This growing alcohol intake is influenced by factors like greater social acceptance, urbanization, evolving lifestyles, and stress coping mechanisms, particularly prevalent among younger demographics. Alcohol intake contributes to chronic pancreatitis by initiating inflammation and harm to pancreatic cells, resulting in fibrosis, obstructions in the ducts, and eventual long-term dysfunction caused by harmful metabolic byproducts. For instance, regarding the situation in 2025, a 2023 survey cited by the Priory Group (a UK-based provider of mental health, addiction, and specialist education services) determined that 25% of UK individuals aged 18–24 now entirely abstain from alcohol, indicating a significant move towards sobriety among the younger demographic. Consequently, the rising intake of alcohol is fueling the expansion of the chronic pancreatitis market.

What Segment Classifications Make Up The Chronic Pancreatitis (CP) Market?

The chronic pancreatitis (cp) market covered in this report is segmented –

1) By Treatment: Analgesic, Artificial Digestive Enzyme, Protein Supplements, Other Treatments

2) By Diagnosis: Computed Tomography (CT) Scan, Magnetic Resonance Cholangiopancreatography, Ultrasound Sonography, Other Diagnosis

3) By Route Of Administration: Oral, Parenteral

4) By End User: Hospitals, Homecare, Other End Users

Subsegments:

1) By Analgesic: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Opioids

2) By Artificial Digestive Enzyme: Pancrelipase, Pancreatin

3) By Protein Supplements: Branched-Chain Amino Acids (BCAA), Whey Protein

4) By Other Treatments: Endoscopic Treatment, Surgery

What Upcoming Trends Are Likely To Define The Future Path Of The Chronic Pancreatitis (CP) Market?

Companies active in the chronic pancreatitis market are prioritizing the development of technological advancements, such as enzyme replacement therapy, to address exocrine pancreatic insufficiency (EPI) linked to chronic pancreatitis. This therapy entails patients orally ingesting pancreatic enzymes to aid digestion when pancreatic function is insufficient. As an illustration, in July 2023, First Wave BioPharma Inc, a US-based clinical-stage biopharmaceutical company, disclosed the results from its Phase 2 SPAN clinical trial. This study investigated an enhanced enteric microgranule delivery formulation of adrulipase for managing exocrine pancreatic insufficiency (EPI) in patients with both cystic fibrosis (CF) and chronic pancreatitis. Adrulipase is a recombinant lipase enzyme derived from the Yarrowia lipolytica yeast, delivered as an oral, non-systemic biologic capsule, specifically engineered to break down fat molecules in the digestive tract of EPI patients to enable their absorption as nutrients.

Which Key Players Are Driving Competition In The Chronic Pancreatitis (CP) Market?

Major companies operating in the chronic pancreatitis (cp) market are Pfizer, Johnson & Johnson, Merck & Co Inc, AbbVie Inc, Sanofi, Bristol-Myers Squibb, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Baxter, CSL Behring, Octapharma AG, Dr. Reddy’s Laboratories, Nestle Health Science, Cerata Pharmaceuticals, Unichem Laboratories Ltd, LGM Pharma, Aptalis Pharmaceutical Technologies, Digestive Care Inc, Akron Biotech

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/chronic-pancreatitis-cp-global-market-report

How Does The Chronic Pancreatitis (CP) Market Perform Across Major Global Regions?

North America was the largest region in the chronic pancreatitis (CP) market in 2025. The regions covered in the chronic pancreatitis (cp) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Chronic Pancreatitis (CP) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21146&type=smp

Browse Through More Reports Similar to the Global Chronic Pancreatitis (CP) Market 2026, By The Business Research Company

Invasive Ductal Carcinoma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/invasive-ductal-carcinoma-therapeutics-global-market-report

Pancreatic Cancer Diagnostic Market Report 2026

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-diagnostic-global-market-report

Exocrine Pancreatic Insufficiency Market Report 2026

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795